ECCO 2019: Vedolizumab vs anti-TNF in biologic-naive uc-patients

This study aimed to compare the real-world clinical effectiveness and safety of vedolizumab, a gut-selective anti-α4β7-integrin, and anti-TNF agents in biologic (bio)-naïve ulcerative colitis (UC) patients. Click and hear the results, presented by Andres Yarur.